Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Multiple Myeloma 26Leukemia, Myeloid, Acute 24Recurrence 12Sarcoma 7Lymphoma, Large B-Cell, Diffuse 6Neoplasm Metastasis 5Neurofibrosarcoma 4Neoplasms, Plasma Cell 4Lymphoma 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Thymoma 2Rhabdoid Tumor 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Melanoma 2Lymphoma, Mantle-Cell 2Liposarcoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Leukemia 2Congenital Abnormalities 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Breast Neoplasms 2Wilms Tumor 1

Interventions

Cyclophosphamide 81fludarabine phosphate 77Peripheral Blood Stem Cell Transplantation 62Mycophenolic Acid 55Tacrolimus 54Whole-Body Irradiation 52Busulfan 51Antilymphocyte Serum 45Cyclosporine 41fludarabine 36Methotrexate 32Filgrastim 32Melphalan 30Radiotherapy 25Methylprednisolone 19Cytarabine 17Cord Blood Stem Cell Transplantation 17Sirolimus 15Azacitidine 15Granulocyte Colony-Stimulating Factor 14Alemtuzumab 14thymoglobulin 13Flow Cytometry 13Etoposide 13Cyclosporins 13Specimen Handling 10Biopsy 10Thiotepa 9Psychiatric Rehabilitation 9Decitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Myeloproliferative Disorders × selinexor × Clear all
NCT07626021 2026-06-04

Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms

Zhongshan Hospital (Xiamen), Fudan University

Phase 2 Not yet recruiting
15 enrolled
Myeloid

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡